Monitoring the use of dabigatran etexilate for stroke prevention: compliance with renal function guidelines
Bryan H. Simpson 1 3 , David M. Reith 2 , Natalie J. Medlicott 1 , Alesha J. Smith 11 School of Pharmacy, University of Otago, Dunedin, New Zealand
2 Otago Medical School, University of Otago, Dunedin, New Zealand
3 Corresponding author. Email: bryan.simpson@postgrad.otago.ac.nz
Journal of Primary Health Care 12(4) 327-334 https://doi.org/10.1071/HC19115
Published: 9 December 2020
Journal Compilation © Royal New Zealand College of General Practitioners 2020 This is an open access article licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
Abstract
INTRODUCTION: Dabigatran etexilate has become widely used in New Zealand, but information relating to when renal function monitoring is being undertaken is lacking.
AIM: To investigate if clinically appropriate renal function monitoring is being undertaken in New Zealand primary care for stroke prevention in non-valvular atrial fibrillation patients prescribed dabigatran etexilate.
METHODS: New Zealand non-valvular atrial fibrillation patients’ prescription and primary care health data were extracted from national administrative databases for the period 1 July 2011 to 31 December 2015. The proportion of patients who had serum creatinine measurements at close proximity to treatment initiation and 12-months post initiation were assessed with 95% confidence intervals (CIs) and compared with Fisher’s exact test. Log-rank tests for univariate analysis (gender, age, ethnicity and deprivation) effects on serum creatinine testing at dabigatran etexilate treatment initiation and 12-months post initiation were performed.
RESULTS: Overall, 1,948 patients who had been dispensed dabigatran etexilate with available primary care health data were identified. A total of 1,752 (89.9% [CI: 88.5–91.2]) patients had a renal function test at dabigatran etexilate initiation. There were 929 (72.8% [CI: 70.2–75.2]) patients who received ≥1 year supply of dabigatran etexilate and of these 207 (22.3% [CI: 19.6.6–25.1]) had a serum creatinine test 1 year after initiation. Demographic univariate analysis yielded insignificant log-rank tests for association with having serum creatinine measurements, except for Pacific Peoples.
DISCUSSION: There appears to be sub-optimal adherence to renal function monitoring for non-valvular atrial fibrillation patients who receive more than 12-months’ treatment with dabigatran etexilate in New Zealand primary care.
Keywords: dabigatran etexilate, non-valvular atrial fibrillation, renal function, stroke
References
[1] Simpson BH, Reith D, Medlicott NJ, Smith A. Deprivation and inequalities lead to worse outcomes with dabigatran etexilate. J Prim Health Care. 2018; 10 303–11.| Deprivation and inequalities lead to worse outcomes with dabigatran etexilate.Crossref | GoogleScholarGoogle Scholar | 31039959PubMed |
[2] Ezekowitz MD, Connolly S, Parekh A, et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J. 2009; 157 805–810.e2.
| Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran.Crossref | GoogleScholarGoogle Scholar | 19376304PubMed |
[3] Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation. 2011; 123 1436–50.
| Dabigatran etexilate: a new oral thrombin inhibitor.Crossref | GoogleScholarGoogle Scholar | 21464059PubMed |
[4] Douxfils J, Ageno W, Samama CM, et al. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. J Thromb Haemost. 2018; 16 209–19.
| Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians.Crossref | GoogleScholarGoogle Scholar | 29193737PubMed |
[5] Simpson BH, Reith DM, Medlicott NJ, et al. Exposure response supports therapeutic drug monitoring for dabigatran etexilate in patients with atrial fibrillation. TH Open. 2019; 3 e210–5.
| Exposure response supports therapeutic drug monitoring for dabigatran etexilate in patients with atrial fibrillation.Crossref | GoogleScholarGoogle Scholar | 31328179PubMed |
[6] Apostolakis S, Guo Y, Lane DA, et al. Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial. Eur Heart J. 2013; 34 3572–9.
| Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial.Crossref | GoogleScholarGoogle Scholar | 23966309PubMed |
[7] Simpson BH, Reith DM, Medlicott NJ, Smith AJ. Choice of renal function estimator influences adverse outcomes with dabigatran etexilate in patients with atrial fibrillation. TH Open. 2018; 2 e420–7.
| Choice of renal function estimator influences adverse outcomes with dabigatran etexilate in patients with atrial fibrillation.Crossref | GoogleScholarGoogle Scholar | 31249970PubMed |
[8] Drouet L, Bal dit Sollier C, Steiner T, et al. Measuring non-vitamin K antagonist oral anticoagulant levels: when is it appropriate and which methods should be used? Int J Stroke. 2016; 11 748–58.
| Measuring non-vitamin K antagonist oral anticoagulant levels: when is it appropriate and which methods should be used?Crossref | GoogleScholarGoogle Scholar | 27412190PubMed |
[9] Gong IY, Kim RB. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. Can J Cardiol. 2013; 29 S24–33.
| Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban.Crossref | GoogleScholarGoogle Scholar | 23790595PubMed |
[10] Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16 31–41.
| Prediction of creatinine clearance from serum creatinine.Crossref | GoogleScholarGoogle Scholar | 1244564PubMed |
[11] Thorne K, Dee S, Jayathissa S. Prescriber compliance with renal function monitoring in patients taking dabigatran (Pradaxa). N Z Med J. 2015; 128 83–88.
| 26913911PubMed |
[12] McBain L, Kyle A. Renal function monitoring in patients prescribed dabigatran in the Compass Health Primary Health Organisation: a quality improvement audit. N Z Med J. 2018; 131 40–47.
| 29518798PubMed |
[13] Best Practice Advocacy Centre. (bpacnz). Clinical audit: renal function testing in people taking dabigatran. Dunedin: bpacnz; 2012. [cited 2019 Sep 5]. Available from: http://www.bpac.org.nz/Audits/Dabigatran-renal.aspx
[14] Best Practice Advocacy Centre. (bpacnz) The use of dabigatran in general practice: a cautious approach is recommended. Best Pract J. 2011; 38 10–27.
[15] Boehringer Ingelheim (N.Z.) Limited. Pradaxa: New Zealand Datasheet. Wellington: Medsafe; 2017. [cited 2017 Nov 1]. Available from: http://www.medsafe.govt.nz/other/copyright.asp
[16] Medsafe Pharmacovigilance Team Monitor renal function in elderly patients taking dabigatran. Prescriber Update. 2015; 36 55
[17] Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018; 39 1330–93.
| The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.Crossref | GoogleScholarGoogle Scholar | 29562325PubMed |
[18] New Zealand Ministry of Health. Pharmaceutical Collection. Wellington, New Zealand: Ministry of Health; 2016.
[19] Best Practice Inc. Decision support for health professionals. Dunedin: bpac Inc.; 2013. [cited 2018 Mar 12]. http://www.bestpractice.net.nz/
[20] Committee for Human Medicinal Products (CHMP). Adequacy of guidance on the elderly regarding medicinal products for human use. Amsterdam: European Medicines Agency; 2007.
[21] Graham MR, Wright MA, Manley HJ. Effectiveness of an amiodarone protocol and management clinic in improving adherence to amiodarone monitoring guidelines. J Pharm Technol 2004; 20 5–10.
| Effectiveness of an amiodarone protocol and management clinic in improving adherence to amiodarone monitoring guidelines.Crossref | GoogleScholarGoogle Scholar |
[22] Schmidt M, Mansfield KE, Bhaskaran K, et al. Adherence to guidelines for creatinine and potassium monitoring and discontinuation following renin–angiotensin system blockade: a UK general practice-based cohort study. BMJ Open. 2017; 7 e012818
| Adherence to guidelines for creatinine and potassium monitoring and discontinuation following renin–angiotensin system blockade: a UK general practice-based cohort study.Crossref | GoogleScholarGoogle Scholar | 29150471PubMed |
[23] Tomlin A, Dovey S, Gauld R, et al. Better use of primary care laboratory services following interventions to ‘market’ clinical guidelines in New Zealand: a controlled before-and-after study. BMJ Qual Saf. 2011; 20 282
| Better use of primary care laboratory services following interventions to ‘market’ clinical guidelines in New Zealand: a controlled before-and-after study.Crossref | GoogleScholarGoogle Scholar | 21228434PubMed |
[24] Piccini JP, Xu H, Cox M, et al. Adherence to guideline-directed stroke prevention therapy for atrial fibrillation is achievable. Circulation. 2019; 139 1497–506.
| Adherence to guideline-directed stroke prevention therapy for atrial fibrillation is achievable.Crossref | GoogleScholarGoogle Scholar | 30700141PubMed |
